Nomura/Instinet lowered its price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $22.00 (from $27.00) while maintaining a Buy rating, following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Syndax Pharmaceuticals (SNDX) PT Lowered to $20 at Citi; Reiterates Buy August 11, 2017 8:56 AM Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c, Beats on Revenues; Offers FY17 OpEx GuidanceAugust 10, 2017 4:15 PM